文献速递心力衰竭与心肌病冠心病

直接重编程改善慢性心肌梗死的心功能并逆转纤维化

Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction.
PubMed 文献 · Circulation · 2022-12-12

该研究在慢性心肌梗死小鼠模型中,通过转基因系统在驻留心脏成纤维细胞中过表达心脏转录因子MGTH,将约2%的成纤维细胞直接重编程为诱导心肌细胞,并抑制促纤维化成纤维细胞状态,从而显著改善心肌收缩并减少纤维化。

要点

  • 体内心脏重编程可将慢性心梗中约2%的驻留成纤维细胞转为诱导心肌细胞。
  • 重编程通过真正转分化而非与心肌细胞融合实现。
  • 重编程抑制促纤维化成纤维细胞并部分通过抑制Meox1发挥抗纤维化作用。

核心结论

  • 心脏重编程可通过心肌再生和减少纤维化来修复慢性心肌梗死。

研究设计与样本

  • 研究采用新型Tcf21iCre/reporter/MGTH2A等转基因小鼠系统,在急性和慢性心肌梗死模型中测试体内心脏重编程。
  • 利用Tcf21iCre/Tomato/MGTH2A和Tcf21iCre/mTmG/MGTH2A小鼠分别分析重编程和融合事件。
  • 通过微阵列和单细胞RNA测序探究重编程修复机制。

主要发现

  • 在慢性心肌梗死中,体内心脏重编程将约2%的驻留心脏成纤维细胞转化为诱导心肌细胞。
  • 大多数诱导心肌细胞通过真正的心脏重编程产生,而非与心肌细胞融合。
  • 心脏重编程显著改善慢性心肌梗死的心肌收缩并减少纤维化。
  • MGTH过表达激活心脏程序并抑制成纤维细胞和炎症特征。
  • 单细胞RNA测序显示驻留心脏成纤维细胞分为7个亚群,慢性心肌梗死中促纤维化成纤维细胞群增加;重编程将促纤维化成纤维细胞转化为静息抗纤维化状态。

临床怎么用

  • 该策略为慢性心肌梗死和心力衰竭提供了通过心肌再生和逆转纤维化的新治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because adult cardiomyocytes have little regenerative capacity, resident cardiac fibroblasts (CFs) synthesize extracellular matrix after myocardial infarction (MI) to form fibrosis, leading to cardiac dysfunction and heart failure. Therapies that can regenerate the myocardium and reverse fibrosis in chronic MI are lacking. The overexpression of cardiac transcription factors, including Mef2c/Gata4/Tbx5/Hand2 (MGTH), can directly reprogram CFs into induced cardiomyocytes (iCMs) and improve cardiac function under acute MI. However, the ability of in vivo cardiac reprogramming to repair chronic MI with established scars is undetermined. METHODS: We generated a novel Tcf21iCre/reporter/MGTH2A transgenic mouse system in which tamoxifen treatment could induce both MGTH and reporter expression in the resident CFs for cardiac reprogramming and fibroblast lineage tracing. We first tested the efficacy of this transgenic system in vitro and in vivo for acute MI. Next, we analyzed in vivo cardiac reprogramming and fusion events under chronic MI using Tcf21iCre/Tomato/MGTH2A and Tcf21iCre/mTmG/MGTH2A mice, respectively. Microarray and single-cell RNA sequencing were performed to determine the mechanism of cardiac repair by in vivo reprogramming. RESULTS: We confirmed the efficacy of transgenic in vitro and in vivo cardiac reprogramming for acute MI. In chronic MI, in vivo cardiac reprogramming converted ≈2% of resident CFs into iCMs, in which a majority of iCMs were generated by means of bona fide cardiac reprogramming rather than by fusion with cardiomyocytes. Cardiac reprogramming significantly improved myocardial contraction and reduced fibrosis in chronic MI. Microarray analyses revealed that the overexpression of MGTH activated cardiac program and concomitantly suppressed fibroblast and inflammatory signatures in chronic MI. Single-cell RNA sequencing demonstrated that resident CFs consisted of 7 subclusters, in which the profibrotic CF population increased under chronic MI. Cardiac reprogramming suppressed fibroblastic gene expression in chronic MI by means of conversion of profibrotic CFs to a quiescent antifibrotic state. MGTH overexpression induced antifibrotic effects partly by suppression of Meox1, a central regulator of fibroblast activation. CONCLUSIONS: These results demonstrate that cardiac reprogramming could repair chronic MI by means of myocardial regeneration and reduction of fibrosis. These findings present opportunities for the development of new therapies for chronic MI and heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Tani, Sadahiro, Yamada, et al. Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction. Circulation. 2022. PMID: 36503256. doi:10.1161/CIRCULATIONAHA.121.058655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。